Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918629 | 0.93 | OPRD1 (0.83) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4932388 | 0.87 | OPRD1 (1.00) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5391009 | 0.85 | OPRD1 (0.80) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5388533 | 0.84 | OPRD1 (0.79) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL14154610 | 0.83 | OPRD1 (0.78) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4931161 | 0.82 | OPRD1 (1.00) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4928072 | 0.82 | OPRD1 (0.81) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4926572 | 0.80 | OPRD1 (0.81) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4924161 | 0.80 | OPRD1 (1.00) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4925624 | 0.80 | OPRD1 (0.76) | OPRD1OPRM1OPRK1KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176903-A1 | Novel Compounds with Analgesic Effect | ASTRAZENECA CANADA INC. (CA) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176903-A1 | Novel Compounds with Analgesic Effect | OPRL1, OPRK1, OPRM1 | OPRD1 4/4885OPRM1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.